EUVIMEDEUVIMED entdecken
Open Access

Safety and Efficacy of Oral Azithromycin for Gastrointestinal Dysmotility in Pediatric Patients

Christopher Brunstetter, Norman E Fenn

The Journal of Pediatric Pharmacology and Therapeutics · 2026-06 · 31 (3) · 407-412

DOI: 10.5863/jppt-25-00064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pediatric Pharmacology and Therapeutics, 2026-06. Verfasst von Christopher Brunstetter und 1 weiteren Autor:innen. Beteiligte Einrichtung: Manchester University College of Health Professions, Nursing, & Pharmacy (CB, NEF3), Fort Wayne, IN. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Pediatric patients with gastrointestinal (GI) dysmotility have limited pharmacologic options due to questionable efficacy and/or safety profiles. The primary objective of this study was to assess the safety of azithromycin in pediatric patients for GI dysmotility. The secondary objective of this study was to evaluate the efficacy of azithromycin in treating GI dysmotility in pediatric patients. METHODS A retrospective cohort analysis was conducted from October 1, 2019, to September 30, 2023. Pediatric patients (18 years and younger) who received azithromycin specifically for GI dysmotility were included in the study. Safety endpoints assessed included description of known common and serious adverse events (ADEs) for azithromycin and corrected QT (QTc) interval exceeding 450 milliseconds (ms) using an electrocardiogram. Demographics, indications, dosing regimens, electrocardiographic data, treatment duration, clinical outcomes, and ADEs were assessed. RESULTS Forty-three patients met inclusion criteria. The cohort was predominantly composed of infants (0–2 years, 55.8%) and female (53.5%). Baseline electrocardiograms were conducted in 41.9% of patients, one of whom had a QTc interval exceeding 450 milliseconds. Median azithromycin dosing was 3 mg/kg/day with a maximum single dose of 300 mg. Treatment duration ranged from 7 days to over 4 years with a median of 56 days. ADEs were described in six patients and were minor in nature with most occurring within two weeks of therapy initiation. Symptom improvement was documented in 18 patients (41.9%). CONCLUSIONS Oral azithromycin may represent a safe and viable option in pediatric patients with GI dysmotility.

Schlagwörter

Stichwörter der Autor:innen

azithromycindysmotilitygastrointestinalpediatricprokinetic

Autor:innen und Institutionen

  • Manchester University College of Health Professions, Nursing, & Pharmacy (CB, NEF3), Fort Wayne, IN.
  • Parkview Regional Medical Center (NEF3), Fort Wayne, IN.

Zitieren

APA

Brunstetter, C., & Fenn, N. E. (2026). Safety and Efficacy of Oral Azithromycin for Gastrointestinal Dysmotility in Pediatric Patients. The Journal of Pediatric Pharmacology and Therapeutics, 31(3), 407-412. https://doi.org/10.5863/jppt-25-00064

Vancouver

Brunstetter C, Fenn NE. Safety and Efficacy of Oral Azithromycin for Gastrointestinal Dysmotility in Pediatric Patients. The Journal of Pediatric Pharmacology and Therapeutics. 2026;31(3):407-412. doi:10.5863/jppt-25-00064

BibTeX
@article{Brunstetter2026,
  author = {Brunstetter, Christopher and Fenn, Norman E},
  title = {Safety and Efficacy of Oral Azithromycin for Gastrointestinal Dysmotility in Pediatric Patients},
  journal = {The Journal of Pediatric Pharmacology and Therapeutics},
  year = {2026},
  volume = {31},
  number = {3},
  pages = {407--412},
  doi = {10.5863/jppt-25-00064}
}
Kostenlos starten →